A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

Breast Cancer Clinical Trial

Official title:

A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK0822 (Odanacatib) in Reducing the Risk of Bone Metastasis in Women With Breast Cancer

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00692458
• Other study ID #: 0822-029
• Secondary ID: 2008_526MK-0822-
• Status: Withdrawn
• Phase: Phase 3
• First received: June 4, 2008
• Last updated: August 11, 2016
• Start date: September 2008
• Est. completion date: September 2008

Study information

• Verified date: November 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test MK0822 on reducing the risk of bone metastasis in women with breast cancer.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 2008
• Est. primary completion date: September 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Confirmed primary State II or Stage III breast cancer

• Patient is not receiving adjuvant chemotherapy (e.g., cyclophosphamide, doxorubicin, carboplatin) at the time of randomization and has not received adjuvant chemotherapy for at least 6 weeks prior to the randomization visit (Visit 2). This inclusion criterion does not include hormone therapy, which is permitted (see inclusion criterion # 7)

• Patient is not receiving hormonal therapy OR if patient is receiving hormonal therapy (e.g., leuprolide, tamoxifen, anastrozole) she is on a stable regimen for at least 3 months at the time of screening (Visit 1). If patient is HER2-positive and is receiving trastuzumab treatment, she must be on a stable regimen for at least 1 month at the time of Visit 1

• Patient is not pregnant or breast-feeding. All women of childbearing potential must have a negative urine pregnancy test at screening (Visit 1)

Exclusion Criteria:

• Bone metastases or history of bone metastases

• Patient has evidence of other distant metastases (e.g., visceral, soft-tissue, or brain)

• Patient has had a prior local or regional recurrence of her breast cancer, or a contralateral tumor. DCIS (ductal carcinoma in-situ), and LCIS (local carcinoma in-situ) in either the ipsilateral or contralateral breast are permitted

• Patient has ANY of the following:

1. is currently receiving a bisphosphonate or other drug therapy for osteoporosis

2. has been treated with an oral bisphosphonate for osteoporosis for more than 3 months within the 2 years prior to Visit 1, or for a total of more than 6 months at any time prior to Visit 1

3. has been treated with an intravenous bisphosphonate within the 12 months prior to Visit 1

• Patient has a history of malignancy other than breast cancer <5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Patients with melanoma, leukemia, lymphoma, and myeloproliferative disorders of any duration are exclusionary

• Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing the informed consent

• Patient is currently participating in or has at any time in the past participated in a breast cancer study with a registered medication (i.e., approved by the regulatory agency in which she resides) being tested for the treatment of breast cancer (an unapproved indication)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Comparator: odanacatib
odanacatib; 5mg oral, once daily for approximately 60 months.
• Comparator: placebo
placebo; oral, once daily for approximately 60 months

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	to assess the effect of treatment with MK0822 5 mg once daily on the risk of developing a first bone metastasis compared to placebo		approximately 60 months (event driven study)	No
Secondary	to assess the effect of treatment with MK0822 5 mg once daily on disease-free survival compared to placebo		approximately 60 months (event driven study)	No